What one share of Recursion Pharmaceuticals holds
Recursion is a clinical-stage TechBio company with a mission to decode biology to radically improve lives. We have advanced a portfolio of differentiated internal programs and strategic partnerships powered by our integrated drug discovery and development platform, the Recursion Operating System (OS).
Recursion Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.11 |
|---|---|
| Profit | −$1.02 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.69 |
| Cash and investments | $1.02 |
| Debt | $0.03 |
| Book value | $1.71 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $0.11 | −$2.87 | $0.18 | −$2.83 | — | −$5.76 |
| 2020 | $0.18 | −$3.99 | $0.27 | −$2.35 | — | −$9.24 |
| 2021 | $0.08 | −$1.49 | $0.32 | −$1.58 | — | $3.19 |
| 2022 | $0.23 | −$1.36 | $0.21 | −$0.69 | — | $2.54 |
| 2023 | $0.21 | −$1.58 | $0.06 | −$1.44 | — | $1.98 |
| 2024 | $0.21 | −$1.69 | $0.05 | −$1.36 | — | $2.61 |
| 2025 | $0.17 | −$1.44 | $0.01 | −$0.85 | — | $2.14 |
Common questions about Recursion Pharmaceuticals
How much does one share of Recursion Pharmaceuticals earn?
Over the last 12 months, Recursion Pharmaceuticals lost $1.02 for each share on $0.11 of sales.
Does Recursion Pharmaceuticals pay a dividend?
Recursion Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Recursion Pharmaceuticals’s book value per share?
Recursion Pharmaceuticals’s book value is $1.71 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Recursion Pharmaceuticals have?
Each share of Recursion Pharmaceuticals has $1.02 of cash and investments and $0.03 of debt, as of June 30, 2026.
What is Recursion Pharmaceuticals’s free cash flow per share?
−$0.69 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Recursion Pharmaceuticals bought back shares?
Recursion Pharmaceuticals’s share count rose about 1974% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.